PositiveID Charging Forward with Expanding Patents and First Successful PCR Results

CHICAGO - March 12, 2015 - PRLog -- Recently, PositiveID (trading under the ticker PSID) has been making some tremendous steps forward with their Firefly real time pathogen detection system. This device has a big advantage over it's competitors because it can make a diagnosis in only 20 minutes, as opposed to the hours that it used to take.The Firefly machine uses a polymerase chain reaction to detect the pathogen in record time. Earlier this month, PositiveID expanded its patent portfolio by filing a new U.S. patent for that same Firefly device. Now with a total of 17 patents, and even more pending, PositiveID has leveraged itself to become a dominate player in the 27.4 billion dollar PCR market.

  If that wasn't enough to draw big attention to the company, on Thursaday March 12th PositiveID announced that it successfully completed its first round of testing on its phase II Firefly prototybe. It's been reported that the Firefly device, which has been repeatedly tested in at standard laboratory volumes, has achieved equivalent results as the lab based PCR instruments. This is a huge accomplishment for the company, and one that should eventually begin to reflect on the value of the share price. The results for the Firefly device are consistent, accurate, and are quickly outpacing the competition.

  Now that PositiveID has confirmed the validity of its device in the market, and had successful tests, the Chairman and CEO of the company, William J. Caragol has expressed that the company is on track and they are continuing to test and develop their device. Everythings on schedule and moving forward for the company here, and we're excited to see where the coming months will take them and the Firefly device.